Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M26.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-3.7
Enterprise Value $M5.7EPS (TTM) $-1.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.310-y EBITDA Growth Rate %--Quick Ratio6.3Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %18.6Current Ratio6.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-81.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-96.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M20.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONCS

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ONCS is held by these investors:

ONCS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mohan-Peterson SheelaChief Legal&Compliance Officer 2017-01-31Buy3,000$0.9927.27view
DHILLON PUNITPresident and CEO 2017-01-31Buy3,000$0.9927.27view
DHILLON PUNITPresident and CEO 2016-07-31Buy3,000$1.44-12.5view
Mohan-Peterson SheelaCL&CO 2016-07-31Buy3,000$1.44-12.5view
DHILLON AVTAR SDirector 2015-10-16Buy10,000$4.36-71.1view
Mohan-Peterson SheelaChief Legal Officer 2015-10-16Buy520$4.24-70.28view
DHILLON PUNITPresident and CEO 2015-10-16Buy10,000$4.25-70.35view
SLANSKY RICHARD BCFO 2015-07-06Buy150,000$6.12-79.41view
DHILLON PUNITPresident and CEO 2015-06-10Buy2,500$6.74-81.31view
MAIDA ANTHONY E IIIDirector 2014-03-20Buy1,140$16.2-92.22view

Press Releases about ONCS :

Quarterly/Annual Reports about ONCS:

News about ONCS:

Articles On GuruFocus.com

More From Other Websites
2:02 pm OncoSec Medical announces the co's Intratumoral Plasmid IL-12 demonstrates effectiveness at... Mar 21 2017
OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor... Mar 21 2017
ONCOSEC MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2017
OncoSec Announces First Technology Access Program Agreement with Inhibrx Mar 14 2017
OncoSec to Present at Scientific and Investment Conferences in March Mar 07 2017
Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot Mar 03 2017
OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017 Mar 02 2017
OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic... Feb 27 2017
OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday,... Feb 24 2017
OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination... Feb 23 2017
OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical... Feb 08 2017
OncoSec to Present at NobleCon13 Jan 26 2017
OncoSec to Present at Investment Conferences in January Jan 03 2017
LifeSci Capital Initiates Coverage of OncoSec Medical Dec 27 2016
ONCOSEC MEDICAL INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors... Dec 16 2016
ONCOSEC MEDICAL INC Financials Dec 14 2016
ONCOSEC MEDICAL INC Files SEC form 10-Q, Quarterly Report Dec 08 2016
ONCOSEC MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 08 2016
OncoSec Announces First Quarter Financial Results for Fiscal Year 2017 Dec 08 2016
ONCOSEC MEDICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Dec 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)